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Abstract
© 2017  The  Author(s).Background:  Mesenchymal  stromal  cells  (MSCs)  have  an  inherent
migratory capacity towards tumor tissue in vivo. With the future objective to quantify the tumor
homing efficacy of MSCs, as first step in this direction we investigated the use of inorganic
nanoparticles (NPs),  in particular ca.  4nm-sized Au NPs,  for  MSC labeling.  Time dependent
uptake efficiencies of NPs at different exposure concentrations and times were determined via
inductively coupled plasma mass spectrometry (ICP-MS). Results: The labeling efficiency of the
MSCs was determined in terms of the amount of exocytosed NPs versus the amount of initially
endocytosed NPs,  demonstrating that  at  high concentrations the internalized Au NPs were
exocytosed  over  time,  leading  to  continuous  exhaustion.  While  exposure  to  NPs  did  not
significantly impair cell viability or expression of surface markers, even at high dose levels,
MSCs were significantly affected in their proliferation and migration potential. These results
demonstrate  that  proliferation  or  migration  assays  are  more  suitable  to  evaluate  whether
labeling  of  MSCs  with  certain  amounts  of  NPs  exerts  distress  on  cells.  However,  despite
optimized conditions  the labeling efficiency varied considerably  in  MSC lots  from different
donors, indicating cell specific loading capacities for NPs. Finally, we determined the detection
limits  of  Au NP-labeled MSCs within murine tissue employing ICP-MS and demonstrate the
distribution and homing of NP labeled MSCs in vivo. Conclusion: Although large amounts of NPs
improve contrast for imaging, duration and extend of labeling needs to be adjusted carefully to
avoid functional deficits in MSCs. We established an optimized labeling strategy for human MSCs
with Au NPs that preserves their migratory capacity in vivo.
http://dx.doi.org/10.1186/s12951-017-0258-5
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